| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $226,455 | 7 | 100 |
Sells | $0 | 0 | 0 |
| Nijhawan Pardeep | Chief Executive Officer | 6 | $223,315 | 0 | $0 | $223,315 |
| Brooks Michael J | President | 1 | $3,140 | 0 | $0 | $3,140 |
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration …
Over the last 12 months, insiders at Edesa Biotech, Inc. have bought $226,455 and sold $0 worth of Edesa Biotech, Inc. stock.
On average, over the past 5 years, insiders at Edesa Biotech, Inc. have bought $123,336 and sold $787,716 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Nijhawan Pardeep (Chief Executive Officer) — $223,315. Brooks Michael J (President) — $3,140.
The last purchase of 10,000 shares for transaction amount of $39,000 was made by Nijhawan Pardeep (Chief Executive Officer) on 2026‑03‑05.
| 2026-03-05 | Nijhawan Pardeep | Chief Executive Officer | 10,000 0.1266% | $3.90 | $39,000 | +57.06% | ||
| 2026-03-04 | Nijhawan Pardeep | Chief Executive Officer | 10,000 0.1194% | $4.26 | $42,560 | +32.55% | ||
| 2026-03-03 | Nijhawan Pardeep | Chief Executive Officer | 10,000 0.1907% | $3.63 | $36,300 | +30.00% | ||
| 2026-03-02 | Nijhawan Pardeep | Chief Executive Officer | 3,000 0.0342% | $2.09 | $6,280 | +147.81% | ||
| 2026-02-27 | Nijhawan Pardeep | Chief Executive Officer | 30,000 0.3632% | $2.22 | $66,696 | +156.82% | ||
| 2026-02-26 | Nijhawan Pardeep | Chief Executive Officer | 20,571 0.251% | $1.58 | $32,480 | +264.52% | ||
| 2026-02-26 | Brooks Michael J | President | 2,000 0.0243% | $1.57 | $3,140 | +264.52% | ||
| 2024-03-25 | Nijhawan Pardeep | Chief Executive Officer | 5,000 0.1509% | $4.00 | $20,000 | +1.55% | ||
| 2023-01-10 | Sale | van der Velden Peter | director | 152,345 0.8038% | $2.63 | $401,368 | -65.60% | |
| 2023-01-09 | Sale | van der Velden Peter | director | 145,129 0.7355% | $2.66 | $386,348 | -67.30% | |
| 2022-06-30 | Pardeep Nijhawan Medicine Professional Corp | Chief Executive Officer | 20,000 0.165% | $1.60 | $32,078 | -29.19% | ||
| 2022-06-29 | Brooks Michael J | President | 3,000 0.0196% | $1.49 | $4,483 | -22.30% | ||
| 2022-06-16 | Brooks Michael J | President | 3,000 0.0189% | $1.61 | $4,817 | -24.24% | ||
| 2022-05-27 | Pardeep Nijhawan Medicine Professional Corp | Chief Executive Officer | 5,000 0.0317% | $1.92 | $9,599 | -28.57% | ||
| 2022-05-25 | Brooks Michael J | President | 3,500 0.0226% | $1.74 | $6,090 | -19.54% | ||
| 2022-05-24 | Pardeep Nijhawan Medicine Professional Corp | Chief Executive Officer | 2,000 0.0133% | $1.80 | $3,600 | -19.43% | ||
| 2022-03-31 | Pardeep Nijhawan Medicine Professional Corp | Chief Executive Officer | 2,000 0.013% | $2.99 | $5,972 | -45.45% | ||
| 2022-03-30 | Pardeep Nijhawan Medicine Professional Corp | Chief Executive Officer | 2,000 0.0148% | $3.05 | $6,098 | -45.30% | ||
| 2022-03-29 | Pardeep Nijhawan Medicine Professional Corp | Chief Executive Officer | 2,000 0.0147% | $3.02 | $6,034 | -44.75% | ||
| 2022-03-18 | Pardeep Nijhawan Medicine Professional Corp | Chief Executive Officer | 2,000 0.0138% | $3.85 | $7,699 | -58.48% |
| Nijhawan Pardeep | Chief Executive Officer | 402702 4.1803% | $918,160.56 | 12 | 0 | +7.13% |
| Brooks Michael J | President | 226870 2.3551% | $517,263.60 | 11 | 0 | <0.0001% |
| Pardeep Nijhawan Medicine Professional Corp | Chief Executive Officer | 594812 6.1746% | $1.36M | 11 | 0 | <0.0001% |
| van der Velden Peter | director | 150275 1.56% | $342,627.00 | 1 | 2 | |
| JOHNSON LORIN K | director | 8524 0.0885% | $19,434.72 | 1 | 0 | |
| Sistilli Carlo | director | 2436 0.0253% | $5,554.08 | 1 | 0 |
$931,435 | 28 | 16.31% | $24.8M | |
Edesa Biotech, Inc. (EDSA) | $226,127 | 22 | -27.62% | $21.96M |
$114,619,342 | 20 | -7.41% | $16.39M | |
$352,389 | 18 | 9.66% | $17.82M | |
$742,412 | 14 | -50.36% | $17.71M |
| Increased Positions | 11 | +40.74% | 263,786 | +9.17% |
| Decreased Positions | 9 | -33.33% | 87,821 | -3.05% |
| New Positions | 6 | New | 221,548 | New |
| Sold Out Positions | 6 | Sold Out | 79,264 | Sold Out |
| Total Postitions | 29 | +7.41% | 3M | +6.12% |
| Rubric Capital Management Lp | $1,031.00 | 8.59% | 687,500 | 0 | 0% | 2025-09-30 |
| Stonepine Capital Management, Llc | $1,031.00 | 8.59% | 687,500 | +687,500 | New | 2025-09-30 |
| Velan Capital Investment Management Lp | $1,031.00 | 8.59% | 687,500 | 0 | 0% | 2025-09-30 |
| Nantahala Capital Management, Llc | $938.00 | 7.81% | 625,000 | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $68.00 | 0.57% | 45,543 | +29,679 | +187.08% | 2025-09-30 |
| Geode Capital Management, Llc | $68.00 | 0.57% | 45,234 | +17,278 | +61.8% | 2025-09-30 |
| Commonwealth Equity Services, Llc | $56.00 | 0.47% | 37,548 | +2,545 | +7.27% | 2025-09-30 |
| Renaissance Technologies Llc | $38.00 | 0.31% | 25,000 | +25,000 | New | 2025-09-30 |
| Susquehanna International Group, Llp | $22.00 | 0.18% | 14,610 | +14,610 | New | 2025-09-30 |
| Citadel Advisors Llc | $21.00 | 0.18% | 14,032 | -9,482 | -40.33% | 2025-09-30 |